<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435253</url>
  </required_header>
  <id_info>
    <org_study_id>01-C06-003</org_study_id>
    <nct_id>NCT00435253</nct_id>
  </id_info>
  <brief_title>US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study</brief_title>
  <official_title>Phase 2 Study of the Biologic Lung Volume Reduction System (BLVR) in Patients With Advanced Upper Lobe Predominant Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeris Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of the 10 mL BLVR System in 1 or 2 treatment sessions (8
      subsegments, 4 in each lung) in patients with advanced upper lobe predominant emphysema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open-label, non-controlled, multi-center Phase 2 Study evaluating the efficacy
      and safety of the 10 mL BLVR System in patients with advanced upper lobe predominant
      emphysema. Twenty patients will be divided into 2 groups of 10 patients each and treated
      under conscious sedation at a total of 8 subsegments. Group 1 will be treated in 4
      subsegments in 1 lung and have a second treatment of 4 subsegments in the other lung 6 to 12
      weeks later. Group 2 will receive treatment at 8 subsegments (4 in each lung) during a single
      treatment session if possible; if not completed in 1 session the remaining subsegments will
      be treated 6 to 12 weeks later. Patients will be followed 96 weeks after completion of the
      final BLVR treatment. All patients will receive standard medical therapy in addition to BLVR
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in gas trapping</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs - Safety of treatment and the procedure</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in vital capacity</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in expiratory flow</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in inspiratory flow</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in dyspnea symptoms (breathlessness)</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in exercise capacity</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in respiratory quality of life</measure>
    <time_frame>12 weeks post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Emphysema</condition>
  <arm_group>
    <arm_group_label>BLVR Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLVR Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BLVR Treatment</intervention_name>
    <description>BLVR Treatment, 10 mL Hydrogel</description>
    <arm_group_label>BLVR Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of advanced upper lobe predominant emphysema

          -  age &gt;/= 40 years

          -  clinically significant dyspnea

          -  failure of standard medical therapy to relieve symptoms (inhaled beta agonist and
             inhaled anticholinergic)

          -  pulmonary function tests within protocol-specified ranges (post bronchodilator FEV1 &lt;
             45% predicted and experiencing &lt; 30% or 300 mL improvement using bronchodilator; TLC &gt;
             110% predicted; RV &gt; 150% predicted)

          -  6 Minute Walk Distance &gt;/= 150 m

        Exclusion Criteria:

          -  alpha-1 protease inhibitor deficiency

          -  homogeneous disease

          -  tobacco use within 4 months of initial visit

          -  body mass index &lt; 15 kg/m2 or &gt; 35 kg/m2

          -  clinically significant asthma, chronic bronchitis or bronchiectasis

          -  allergy or sensitivity to procedural components

          -  pregnant, lactating or unwilling to use birth control if required

          -  prior lung volume reduction surgery, lobectomy, pneumonectomy, lung transplant,
             endobronchial valve placement, airway stent placement or pleurodesis

          -  comorbid condition that could adversely influence outcomes

          -  inability to tolerate bronchoscopy under conscious sedation (or anesthesia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Pinto-Plata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steward St. Elizabeth's Medical Center of Boston, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard Criner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Lung Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Gotfried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlie Strange, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Univ South Carolina Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Dransfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ of Alabama Birmingham Lung Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham Lung Health Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas St Elizabeth's Med Cen</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>01940</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ingenito EP, Berger RL, Henderson AC, Reilly JJ, Tsai L, Hoffman A. Bronchoscopic lung volume reduction using tissue engineering principles. Am J Respir Crit Care Med. 2003 Mar 1;167(5):771-8. Epub 2002 Oct 11.</citation>
    <PMID>12406835</PMID>
  </reference>
  <reference>
    <citation>Reilly J, Washko G, Pinto-Plata V, Velez E, Kenney L, Berger R, Celli B. Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest. 2007 Apr;131(4):1108-13.</citation>
    <PMID>17426216</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2007</study_first_posted>
  <last_update_submitted>October 21, 2011</last_update_submitted>
  <last_update_submitted_qc>October 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>emphysema</keyword>
  <keyword>COPD</keyword>
  <keyword>lung volume reduction</keyword>
  <keyword>NETT</keyword>
  <keyword>BLVR</keyword>
  <keyword>biologic lung volume reduction</keyword>
  <keyword>bronchoscopic lung volume reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

